Dupixent becomes ninefold blockbuster
Sales of Sanofi’s multi-incidation drug, Dupixent, are growing and on track to pass a huge milestone in 2023.
by christian bundgaard, translated by daniel pedersen
French Sanofi’s best-selling product, Dupixent (dupilumab), which has been approved for a number of indications, just keeps breaking sales records.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP recommends expanded approval of Dupixent
For subscribers
.jpg&w=384&q=75)
